Periodontal inflamed surface area in oral cavity associated with febrile neutropenia in patients with hematologic malignancy undergoing chemotherapy
- PMID: 35169215
- PMCID: PMC8847642
- DOI: 10.1038/s41598-022-06485-0
Periodontal inflamed surface area in oral cavity associated with febrile neutropenia in patients with hematologic malignancy undergoing chemotherapy
Abstract
Febrile neutropenia (FN) is an infectious complication that develops during chemotherapy. Although the oral cavity can be an important infection route, it is unknown whether the oral environment is associated with FN. The present study examined the relationship between the oral environment using periodontal inflamed surface area (PISA), a new periodontal disease parameter, and FN in hematologic cancer patients undergoing chemotherapy. In this retrospective cohort study, 157 patients were divided into FN onset during chemotherapy (n = 75) and the FN negative groups (n = 82). The associations of risk factors related to the intraoral environment were assessed. Logistic regression analysis showed that types of blood cancer (odds ratio 1.98; P < 0.01), use of a high-risk regimen (odds ratio 4.44; P < 0.05), prophylaxis treatment with human granulocyte colony-stimulating factor (G-CSF) (odds ratio 4.15; P < 0.01) and PISA (odds ratio 1.02; P < 0.01) were independent factors associated with FN onset. Finally, propensity score matching was performed between two groups; 37 matched pairs were generated. PISA was significantly higher in the FN group than the FN negative group. There was a significant relationship between PISA and FN onset (P = 0.035). The present findings indicate that periodontitis treatment before starting cancer treatment is recommended as supportive care for preventing FN onset during chemotherapy.
© 2022. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.Wien Klin Wochenschr. 2016 Apr;128(7-8):238-47. doi: 10.1007/s00508-015-0917-1. Epub 2016 Jan 8. Wien Klin Wochenschr. 2016. PMID: 26745973 Free PMC article.
-
Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.Support Care Cancer. 2021 Apr;29(4):2179-2186. doi: 10.1007/s00520-020-05715-3. Epub 2020 Sep 3. Support Care Cancer. 2021. PMID: 32880732 Free PMC article.
-
Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The CSR FENCE score.Int J Cancer. 2020 Jan 15;146(2):321-328. doi: 10.1002/ijc.32249. Epub 2019 Mar 28. Int J Cancer. 2020. PMID: 30839100
-
A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group.J Natl Compr Canc Netw. 2017 Dec;15(12):1543-1550. doi: 10.6004/jnccn.2017.7038. J Natl Compr Canc Netw. 2017. PMID: 29223991 Review.
-
Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.BMC Cancer. 2021 May 27;21(1):621. doi: 10.1186/s12885-021-08258-w. BMC Cancer. 2021. PMID: 34044798 Free PMC article.
Cited by
-
Pre-Chemotherapy Dental Screening: Is There Additional Diagnostic Value for a Panoramic Radiograph?Dent J (Basel). 2023 May 4;11(5):122. doi: 10.3390/dj11050122. Dent J (Basel). 2023. PMID: 37232773 Free PMC article.
-
Palliative Care in Patients with Hematological Malignancies.Florence Nightingale J Nurs. 2023 Apr;31(Supp1):S59-S65. doi: 10.5152/FNJN.2023.23046. Florence Nightingale J Nurs. 2023. PMID: 37162056 Free PMC article.
-
Incidence of oral manifestations in hematological malignancy patients undergoing chemotherapy: prospective cohort study.Med Oral Patol Oral Cir Bucal. 2025 Jan 1;30(1):e17-e23. doi: 10.4317/medoral.26652. Med Oral Patol Oral Cir Bucal. 2025. PMID: 39724524 Free PMC article.
-
Impact of Fusobacterium nucleatum in the treatment of cancer, including radiotherapy and its future potential in esophageal cancer.J Radiat Res. 2024 Dec 16;65(Supplement_1):i126-i134. doi: 10.1093/jrr/rrae061. J Radiat Res. 2024. PMID: 39679879 Free PMC article. Review.
-
Quantitative Evaluation of Periodontitis for Predicting the Occurrence of Postoperative Pneumonia After Oncologic Esophagectomy.Ann Surg Oncol. 2023 Dec;30(13):8216-8222. doi: 10.1245/s10434-023-14030-0. Epub 2023 Aug 1. Ann Surg Oncol. 2023. PMID: 37526753
References
-
- Hong CHL, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines On behalf of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) Support. Care Cancer. 2019;27:3949–3967. - PubMed
-
- Kolenbrander PE, et al. Bacterial interactions and successions during plaque development. Periodontol. 2006;2000(42):47–79. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous